{"id":"adjuvant-durvalumab","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"3-5","effect":"Pneumonitis"},{"rate":"15-20","effect":"Diarrhea"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Rash"},{"rate":"2-5","effect":"Immune-mediated hepatitis"},{"rate":"1-3","effect":"Immune-mediated colitis"}]},"_chembl":{"chemblId":"CHEMBL3301587","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T13:01:00.440230","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Durvalumab binds to programmed death ligand 1 (PD-L1) expressed on tumor cells and immune cells, preventing engagement with PD-1 and PD-L2 receptors on T cells. This blockade reverses tumor-mediated immune suppression, allowing cytotoxic T lymphocytes to recognize and eliminate cancer cells. In the adjuvant setting, durvalumab is used post-operatively to reduce recurrence risk in early-stage disease.","oneSentence":"Durvalumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/PD-L2 on immune cells, thereby restoring anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:11.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy"},{"name":"Adjuvant treatment of resected stage II-III gastric or gastroesophageal junction adenocarcinoma"}]},"_fixedFields":["pubmed(83)","modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT06498635","phase":"PHASE3","title":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-01","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":306},{"nctId":"NCT06732401","phase":"PHASE3","title":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-07","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":630},{"nctId":"NCT03410615","phase":"PHASE2","title":"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-05-28","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":129},{"nctId":"NCT07195695","phase":"PHASE3","title":"Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-01-16","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT05629585","phase":"PHASE3","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-11-28","conditions":"Breast Cancer","enrollment":1174},{"nctId":"NCT06284317","phase":"PHASE3","title":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2025-01-15","conditions":"Non Small Cell Lung Cancer","enrollment":290},{"nctId":"NCT03732677","phase":"PHASE3","title":"Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-16","conditions":"Muscle Invasive Bladder Cancer","enrollment":1063},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT05061550","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-04-14","conditions":"Non-small Cell Lung Cancer","enrollment":630},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT03847428","phase":"PHASE3","title":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-29","conditions":"Hepatocellular Carcinoma","enrollment":908},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT07149363","phase":"PHASE2","title":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2026-02","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":65},{"nctId":"NCT04585477","phase":"PHASE2","title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-04-08","conditions":"Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II","enrollment":80},{"nctId":"NCT03141359","phase":"PHASE2","title":"Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2017-05-12","conditions":"Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer","enrollment":61},{"nctId":"NCT03768570","phase":"PHASE2","title":"Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2019-10-25","conditions":"Bladder Cancer","enrollment":82},{"nctId":"NCT06484491","phase":"NA","title":"IMPT Dose Escalation for NSCLC (HyDose)","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-09-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":87},{"nctId":"NCT05925530","phase":"PHASE2","title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-22","conditions":"Non-small Cell Lung Cancer","enrollment":142},{"nctId":"NCT04432142","phase":"","title":"Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maastricht Radiation Oncology","startDate":"2021-04-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT04748419","phase":"PHASE1, PHASE2","title":"Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2021-07-15","conditions":"Lung Cancer, Carcinoma, Non-Small Cell Lung","enrollment":6},{"nctId":"NCT07247786","phase":"PHASE2","title":"Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)","status":"NOT_YET_RECRUITING","sponsor":"Fundación GECP","startDate":"2026-03-15","conditions":"Non Small Cell Lung Cancer, Respiratory Tract Neoplasm","enrollment":68},{"nctId":"NCT05380713","phase":"PHASE2","title":"......SMARTEST Trial......","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2022-05-03","conditions":"Mesothelioma, Malignant","enrollment":30},{"nctId":"NCT04592913","phase":"PHASE3","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-17","conditions":"Gastrointestinal Neoplasms, Esophagogastric Junction","enrollment":957},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT06218511","phase":"PHASE1","title":"A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2022-11-22","conditions":"Hepatocellular Carcinoma","enrollment":10},{"nctId":"NCT04960709","phase":"PHASE3","title":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-08-05","conditions":"Muscle Invasive Bladder Cancer","enrollment":712},{"nctId":"NCT02726997","phase":"PHASE1, PHASE2","title":"Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-07-06","conditions":"Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7","enrollment":18},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT03249142","phase":"PHASE1, PHASE2","title":"Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2017-10-18","conditions":"Ovarian Cancer","enrollment":69},{"nctId":"NCT02572843","phase":"PHASE2","title":"Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2016-06-16","conditions":"NSCLC Non-small Cell Lung Cancer","enrollment":68},{"nctId":"NCT03237377","phase":"PHASE2","title":"Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-12-12","conditions":"Non-Small Cell Lung Cancer","enrollment":9},{"nctId":"NCT04940286","phase":"PHASE2","title":"Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-28","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8","enrollment":13},{"nctId":"NCT02826434","phase":"PHASE1","title":"Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2016-08-18","conditions":"Breast Cancer","enrollment":22},{"nctId":"NCT05701488","phase":"PHASE1","title":"SIRT With Tremelimumab and Durvalumab for Resectable HCC","status":"RECRUITING","sponsor":"Jiping Wang, MD, PhD","startDate":"2023-04-21","conditions":"Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer","enrollment":20},{"nctId":"NCT02273375","phase":"PHASE3","title":"Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-02-24","conditions":"Non-Small Cell Lung Cancer","enrollment":1415},{"nctId":"NCT03740893","phase":"PHASE2","title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-10-15","conditions":"Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD","enrollment":119},{"nctId":"NCT03529422","phase":"PHASE2","title":"Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-10-07","conditions":"Larynx, Lip, Oral Cancer","enrollment":18},{"nctId":"NCT04062708","phase":"PHASE2","title":"CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-03-10","conditions":"Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","enrollment":38},{"nctId":"NCT03800134","phase":"PHASE3","title":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-06","conditions":"Non-Small Cell Lung Cancer","enrollment":825},{"nctId":"NCT06998719","phase":"PHASE2","title":"Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Bi Nan","startDate":"2025-07","conditions":"Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma","enrollment":80},{"nctId":"NCT04441138","phase":"PHASE2","title":"Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2021-02-25","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":10},{"nctId":"NCT05742607","phase":"PHASE2","title":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","status":"RECRUITING","sponsor":"Innate Pharma","startDate":"2023-06-23","conditions":"Non Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT03406650","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2018-05-15","conditions":"Urothelial Cancer","enrollment":61},{"nctId":"NCT05239169","phase":"PHASE2","title":"Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2022-05-23","conditions":"Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma","enrollment":40},{"nctId":"NCT06045975","phase":"PHASE2","title":"Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-28","conditions":"HCC - Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT03875573","phase":"PHASE2","title":"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2019-11-06","conditions":"Luminal B","enrollment":147},{"nctId":"NCT06094140","phase":"PHASE2","title":"NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2022-05-20","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT05255653","phase":"PHASE2, PHASE3","title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2021-11-11","conditions":"Endometrial Cancer","enrollment":1615},{"nctId":"NCT02891161","phase":"PHASE1, PHASE2","title":"Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder","status":"TERMINATED","sponsor":"Monika Joshi, MD","startDate":"2016-11-16","conditions":"Urothelial Cancer","enrollment":26},{"nctId":"NCT05034887","phase":"PHASE2","title":"Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-01-31","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT06341764","phase":"PHASE2","title":"Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2023-09-01","conditions":"Cholangiocarcinoma","enrollment":38},{"nctId":"NCT03116529","phase":"PHASE1, PHASE2","title":"Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2017-06-21","conditions":"Soft Tissue Sarcoma","enrollment":22},{"nctId":"NCT05667298","phase":"PHASE1","title":"Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Manitoba","startDate":"2023-03-01","conditions":"Esophageal Cancer","enrollment":11},{"nctId":"NCT05440864","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Resectable HCC","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-10-26","conditions":"Hepatocellular Carcinoma","enrollment":28},{"nctId":"NCT04385368","phase":"PHASE3","title":"Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":89},{"nctId":"NCT06490107","phase":"PHASE2","title":"Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-24","conditions":"Biliary Tract Cancer","enrollment":40},{"nctId":"NCT04159974","phase":"PHASE2","title":"RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus","status":"UNKNOWN","sponsor":"University of Cologne","startDate":"2019-09-30","conditions":"Esophageal Adenocarcinoma","enrollment":56},{"nctId":"NCT03572400","phase":"PHASE2","title":"Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Do-Youn Oh","startDate":"2018-11-29","conditions":"Pancreatic Cancer","enrollment":71},{"nctId":"NCT02762006","phase":"PHASE1","title":"Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Moshe Ornstein","startDate":"2016-12-20","conditions":"Renal Cell Carcinoma, Kidney Cancer","enrollment":29},{"nctId":"NCT04221555","phase":"PHASE2","title":"Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2020-05-13","conditions":"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":68},{"nctId":"NCT03871153","phase":"PHASE2","title":"Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Greg Durm, MD","startDate":"2019-08-02","conditions":"Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer","enrollment":7},{"nctId":"NCT05451173","phase":"PHASE1, PHASE2","title":"Combining ICI With SBRT or HypoFrx-RT for ES NSCLC","status":"UNKNOWN","sponsor":"Alexander Chi","startDate":"2023-10-09","conditions":"Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I","enrollment":83},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT04625699","phase":"PHASE2","title":"Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment","status":"WITHDRAWN","sponsor":"Catherine Shu","startDate":"2022-12","conditions":"Nonsmall Cell Lung Cancer","enrollment":""},{"nctId":"NCT05382741","phase":"PHASE2","title":"Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial","status":"UNKNOWN","sponsor":"Ospedale Policlinico San Martino","startDate":"2022-03-02","conditions":"Colorectal Cancer Stage IV, No Evidence of Disease State","enrollment":182},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT04646837","phase":"PHASE1, PHASE2","title":"Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-05-01","conditions":"Non-small Cell Lung Cancer","enrollment":20},{"nctId":"NCT03737968","phase":"PHASE2","title":"Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-01-02","conditions":"Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx","enrollment":48},{"nctId":"NCT04107168","phase":"","title":"Microbiome Immunotherapy Toxicity and Response Evaluation","status":"UNKNOWN","sponsor":"CCTU- Cancer Theme","startDate":"2020-07-08","conditions":"Melanoma, Renal Cancer, Lung Cancer","enrollment":1800},{"nctId":"NCT03853187","phase":"PHASE2","title":"Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-09-19","conditions":"Non-small Cell Lung Cancer","enrollment":20},{"nctId":"NCT03162224","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-06-26","conditions":"Head and Neck Cancer, Human Papilloma Virus","enrollment":35},{"nctId":"NCT04001413","phase":"PHASE2","title":"Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-09-17","conditions":"HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma","enrollment":""},{"nctId":"NCT02794883","phase":"PHASE2","title":"Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-11-01","conditions":"Malignant Glioma, Recurrent Glioblastoma","enrollment":36},{"nctId":"NCT04762030","phase":"PHASE2","title":"Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-02-08","conditions":"Non Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT03899610","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-07-04","conditions":"Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV","enrollment":24},{"nctId":"NCT04145193","phase":"PHASE2","title":"Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2020-10-01","conditions":"Microsatellite-stable Colorectal Cancer","enrollment":""},{"nctId":"NCT03038477","phase":"PHASE2","title":"A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2017-06-12","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT03288532","phase":"PHASE3","title":"Renal Adjuvant MultiPle Arm Randomised Trial","status":"RECRUITING","sponsor":"University College, London","startDate":"2018-07-19","conditions":"Renal Cell Carcinoma","enrollment":1750},{"nctId":"NCT04465968","phase":"PHASE3","title":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2020-09-01","conditions":"Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III","enrollment":84},{"nctId":"NCT02520453","phase":"PHASE2","title":"Adjuvant Durvalumab for Esophageal Cancer","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-02","conditions":"Esophageal Cancer","enrollment":86},{"nctId":"NCT03694236","phase":"PHASE1, PHASE2","title":"Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2019-02-12","conditions":"Potentially Resectable Stage II/IIIa NSCLC","enrollment":39},{"nctId":"NCT03130764","phase":"PHASE2","title":"Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2017-03","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03051906","phase":"PHASE1, PHASE2","title":"Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-01","conditions":"Head and Neck Neoplasms","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":83,"recentPublications":[{"date":"2026 Mar 14","pmid":"41880691","title":"CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).","journal":"Lung cancer (Amsterdam, Netherlands)"},{"date":"2026 Feb 26","pmid":"41763495","title":"Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC.","journal":"International journal of radiation oncology, biology, physics"},{"date":"2026 Feb 6","pmid":"41681998","title":"Perioperative Immune-Checkpoint Inhibition in Renal Cell Carcinoma: Lessons Learned and Future Directions.","journal":"Cancers"},{"date":"2026 Feb 12","pmid":"41678313","title":"FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle Invasive Bladder Cancer.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"date":"2026 Mar 10","pmid":"41650357","title":"Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adjuvant durvalumab","genericName":"Adjuvant durvalumab","companyName":"ETOP IBCSG Partners Foundation","companyId":"etop-ibcsg-partners-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Durvalumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/PD-L2 on immune cells, thereby restoring anti-tumor immune responses. Used for Adjuvant treatment of stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy, Adjuvant treatment of resected stage II-III gastric or gastroesophageal junction adenocarcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}